Key Details
Price
$4.40Annual ROE
-817.78%Beta
1.51Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Mar 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113963&wire=1 or contact Joseph E. Levi, Esq.
SAN FRANCISCO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v. Humacyte, Inc., et al., alleges that the company misled investors about the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel (ATEV) and the regulatory compliance of its manufacturing facilities.
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113941&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113928&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113896&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113883&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113842&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113788&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113824&wire=1 or contact Joseph E. Levi, Esq.
FAQ
- What is the primary business of Humacyte?
- What is the ticker symbol for Humacyte?
- Does Humacyte pay dividends?
- What sector is Humacyte in?
- What industry is Humacyte in?
- What country is Humacyte based in?
- When did Humacyte go public?
- Is Humacyte in the S&P 500?
- Is Humacyte in the NASDAQ 100?
- Is Humacyte in the Dow Jones?
- When was Humacyte's last earnings report?
- When does Humacyte report earnings?
- Should I buy Humacyte stock now?